---
title: "Management Metastatic UC"
date: "2024-01-03 11:03:00"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[urothelial carcinoma]]

# Management Metastatic UC

Cisplatin-based chemo is the preferred initial tx (ddMVAC, GC), if eligible 1st line: GC preferred over MVAC d/t equal efficacy w/ less toxicity (less neutropenia, neutropenic sepsis, mucositis) (JCO 2000:18:3068). ddMVAC (q2wk w/ GCSF support) has â†‘ RR, â†“ toxicity compared to MVAC (JCO 2001;19:2638)
If cisplatin ineligible (CrCl â‰¤60 mL/min; ECOG PS â‰¥2; Grade 2 hearing loss/neuropathy; NYHA HF class â‰¥3) but platinum eligible: Use gemcitabine + carboplatin (JCO 2012;30:191) OR if PD-L1 positive: Pembrolizumab (Lancet Onc 2017;18:1483) or atezolizumab (Lancet 2017;389:67)
If platinum ineligible (CrCl <30 mL/min; ECOG PS >3; neuropathy grade >3; NYHA HF Class >3; ECOG PS 2 & CrCl <30 mL/min): Pembrolizumab or atezolizumab
Maintenance avelumab â†‘ OS after partial response or stable dz to platinum (NEJM 2020;383:1218)
2nd line: FDA-approved agents include pembrolizumab a/w â†‘ OS vs. chemo (NEJM 2017;376:1015), nivolumab a/w 24% RR (Lancet Onc 2016;17:1590), avelumab a/w 17% RR (Lancet Onc 2018;19:51). If FGFR2/3 genetic alterations, erdafitinib can be used post platinum, a/w 40% RR (NEJM 2019;381:338), but usually deferred until 3rd or 4th line
3rd line: Enfortumab vedotin a/w â†‘ OS vs. chemo post platinum & PD-1/L1 inhibitor (NEJM 2021;384:1125); Sacituzumab govitecan a/w RR 27% (JCO 2021;39(22):2474)
Can consider gemcitabine, docetaxel, paclitaxel monotherapy in later tx lines

- [[ddMVAC]]

### Siblings

- [[Epidemiology-of-urothelial carcinoma]]
- [[Etiology and clinical manifestations-of-urothelial carcinoma]]
- [[Pathologic Subtypes-of-urothelial carcinoma]]
- [[Workup-of-urothelial carcinoma]]
- [[Staging and prognosis-of-urothelial carcinoma]]
- [[Management of Nonmuscle invasive UC]]
- [[Management of Muscle invasive UC]]
- [[Management Metastatic UC]]
- [[Cancers of the renal pelvis and ureter]]
- [[Molecular biology and targeted therapy-of-urothelial carcinoma]]

